{
    "organizations": [],
    "uuid": "bcee63e308e352d8bcc19fe30d9967487730c951",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-nicox-q1-net-revenue-at-0075-milli/brief-nicox-q1-net-revenue-at-0-075-million-euros-idUSFWN1SA1J7",
    "ord_in_thread": 0,
    "title": "BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 4 (Reuters) - NICOX SA:\n* AS OF MARCH 31, 2018, THE GROUP HAD CASH AND CASH EQUIVALENTS OF €36.3 MILLION AS COMPARED WITH €41.4 MILLION AT DECEMBER 31, 2017\n* ZERVIATE EXPECTED TO BE LAUNCHED IN U.S. BY EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON\n* NET REVENUE FOR THE FIRST QUARTER OF 2018 WAS €0.075 MILLION\n* NCX 470 U.S. INVESTIGATIONAL NEW DRUG (IND) SUBMISSION ENABLING PHASE 2 CLINICAL STUDY IN GLAUCOMA PATIENTS PLANNED IN Q3 2018.\n* NCX 4251 U.S. IND SUBMISSION ENABLING PHASE 2 CLINICAL STUDY IN BLEPHARITIS PATIENTS PLANNED IN Q1 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-04T13:36:00.000+03:00",
    "crawled": "2018-05-05T12:08:50.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "nicox",
        "sa",
        "march",
        "group",
        "cash",
        "cash",
        "equivalent",
        "million",
        "compared",
        "million",
        "december",
        "zerviate",
        "expected",
        "launched",
        "eyevance",
        "pharmaceutical",
        "fall",
        "allergy",
        "season",
        "net",
        "revenue",
        "first",
        "quarter",
        "million",
        "ncx",
        "investigational",
        "new",
        "drug",
        "ind",
        "submission",
        "enabling",
        "phase",
        "clinical",
        "study",
        "glaucoma",
        "patient",
        "planned",
        "q3",
        "ncx",
        "ind",
        "submission",
        "enabling",
        "phase",
        "clinical",
        "study",
        "blepharitis",
        "patient",
        "planned",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}